Compare Stocks

Date Range: 

 CatalentCureVacUCBHorizon Therapeutics PublicAlnylam Pharmaceuticals
SymbolNYSE:CTLTNASDAQ:CVACOTCMKTS:UCBJFNASDAQ:HZNPNASDAQ:ALNY
Price Information
Current Price$108.61$61.94$96.65$94.61$176.89
52 Week RangeBuyHoldHoldBuyBuy
MarketRank™
Overall Score1.80.70.71.91.4
Analysis Score2.41.10.02.41.3
Community Score2.42.22.33.33.3
Dividend Score0.00.00.00.00.0
Ownership Score1.70.00.01.71.7
Earnings & Valuation Score2.50.01.31.90.6
Analyst Ratings
Consensus RecommendationBuyHoldHoldBuyBuy
Consensus Price Target$125.13$51.67N/A$111.36$172.07
% Upside from Price Target15.21% upside-16.59% downsideN/A17.71% upside-2.72% downside
Trade Information
Market Cap$18.50 billion$11.58 billion$18.27 billion$21.27 billion$20.79 billion
Beta1.45N/A0.561.111.25
Average Volume1,044,8231,134,5801871,813,189634,463
Sales & Book Value
Annual Revenue$3.09 billion$55.83 million$6.11 billion$2.20 billion$492.85 million
Price / Sales5.98207.372.999.6642.19
Cashflow$3.73 per shareN/A$5.95 per share$5.28 per shareN/A
Price / Cash29.10N/A16.2517.91N/A
Book Value$18.71 per share$4.49 per share$42.71 per share$18.24 per share$8.75 per share
Price / Book5.8013.802.265.1920.22
Profitability
Net Income$173 million$-147,500,000.00$836.16 million$389.80 million$-858,280,000.00
EPS$1.88($1.12)$6.12$3.88($7.46)
Trailing P/E Ratio36.57N/A15.7981.56N/A
Forward P/E Ratio33.11N/A15.9218.26N/A
P/E Growth1.93N/AN/A1.85N/A
Net Margins14.43%N/AN/A12.81%-153.49%
Return on Equity (ROE)13.88%N/AN/A22.28%-76.92%
Return on Assets (ROA)5.57%N/AN/A12.91%-26.27%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.85%0.04%0.32%0.66%0.21%
Current Ratio2.44%5.61%1.27%2.37%4.99%
Quick Ratio1.97%5.55%0.97%2.06%4.84%
Ownership Information
Institutional Ownership Percentage96.43%7.16%N/A86.49%91.85%
Insider Ownership Percentage1.00%N/AN/A3.20%2.30%
Miscellaneous
Employees13,9004558,3711,3951,453
Shares Outstanding170.34 million186.91 million189.02 million224.77 million117.55 million
Next Earnings Date8/30/2021 (Estimated)7/27/2021 (Estimated)6/24/2021 (Estimated)8/4/2021 (Estimated)8/5/2021 (Estimated)
OptionableOptionableNot OptionableNot OptionableOptionableOptionable
SourceHeadline
Global Oligonucleotide Therapy Market Report 2021-2025 & 2030: Focus on Antisense Oligonucleotide, Aptamer, & OthersGlobal Oligonucleotide Therapy Market Report 2021-2025 & 2030: Focus on Antisense Oligonucleotide, Aptamer, & Others
prnewswire.com - June 18 at 6:25 PM
Global Antisense & RNAi Therapeutics Market Report 2021-2025 & 2030Global Antisense & RNAi Therapeutics Market Report 2021-2025 & 2030
prnewswire.com - June 18 at 6:25 PM
Interesting ALNY Put And Call Options For August 20thInteresting ALNY Put And Call Options For August 20th
nasdaq.com - June 18 at 6:25 PM
Atsena expands leadership team with chief medical officerAtsena expands leadership team with chief medical officer
mmm-online.com - June 17 at 2:39 PM
Global Antisense & RNAi Therapeutics Market Report 2021: Market is Expected to Reach $1.79 Billion in 2025 at a CAGR of 11% - Forecast to 2030Global Antisense & RNAi Therapeutics Market Report 2021: Market is Expected to Reach $1.79 Billion in 2025 at a CAGR of 11% - Forecast to 2030
ca.finance.yahoo.com - June 17 at 9:38 AM
Whats Next For Alnylam Stock After The Recent 22% Rise?What's Next For Alnylam Stock After The Recent 22% Rise?
nasdaq.com - June 14 at 3:25 AM
What’s Next For Alnylam Stock After The Recent 22% Rise?What’s Next For Alnylam Stock After The Recent 22% Rise?
forbes.com - June 11 at 12:33 PM
Alnylam Pharmaceuticals (NASDAQ:ALNY) Shares Gap Down to $163.26Alnylam Pharmaceuticals (NASDAQ:ALNY) Shares Gap Down to $163.26
americanbankingnews.com - June 11 at 10:46 AM
BRIEF-Alnylam Announces New Data From ATTR Amyloidosis Programs At The Peripheral Nerve Societys MeetingBRIEF-Alnylam Announces New Data From ATTR Amyloidosis Programs At The Peripheral Nerve Society's Meeting
msn.com - June 7 at 8:32 AM
2 Biotech Stocks ARK Invest Bought in June2 Biotech Stocks ARK Invest Bought in June
finance.yahoo.com - June 7 at 8:32 AM
Alnylam Announces New Data from ATTR Amyloidosis Programs at the Peripheral Nerve Society’s 2021 Annual MeetingAlnylam Announces New Data from ATTR Amyloidosis Programs at the Peripheral Nerve Society’s 2021 Annual Meeting
finance.yahoo.com - June 7 at 8:32 AM
BIOTECanada Board Announces Addition of Directors and New ChairBIOTECanada Board Announces Addition of Directors and New Chair
pharmiweb.com - June 3 at 6:03 PM
Alnylam Completes Enrollment in APOLLO-B Phase 3 Study of Patisiran in Transthyretin-Mediated (ATTR) Amyloidosis Patients with CardiomyopathyAlnylam Completes Enrollment in APOLLO-B Phase 3 Study of Patisiran in Transthyretin-Mediated (ATTR) Amyloidosis Patients with Cardiomyopathy
finance.yahoo.com - June 1 at 8:18 AM
Dicerna Announces FDA Acceptance of Lilly’s Investigational New Drug (IND) Application for LY3819469Dicerna Announces FDA Acceptance of Lilly’s Investigational New Drug (IND) Application for LY3819469
uk.finance.yahoo.com - May 27 at 7:37 AM
A springboard to the future: Genentech, Sanofi and Alnylam execs sound off on pharmas evolving back-to-work plansA 'springboard' to the future: Genentech, Sanofi and Alnylam execs sound off on pharma's evolving back-to-work plans
fiercepharma.com - May 25 at 2:49 PM
Dicerna Announces Boehringer Ingelheim’s Acceptance of Candidate for Development Under RNAi Research Collaboration and License AgreementDicerna Announces Boehringer Ingelheim’s Acceptance of Candidate for Development Under RNAi Research Collaboration and License Agreement
au.finance.yahoo.com - May 24 at 7:44 AM
RNA Based Therapeutics Market Provides Company Profiles which includes Sales, Price, Revenue and Gross Margin 2021 to 2027RNA Based Therapeutics Market Provides Company Profiles which includes Sales, Price, Revenue and Gross Margin 2021 to 2027
marketwatch.com - May 21 at 3:36 PM
Alnylam Pharmaceuticals, Inc.s (NASDAQ:ALNY) Shift From Loss To ProfitAlnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Shift From Loss To Profit
finance.yahoo.com - May 21 at 8:26 AM
Prevnar 13Prevnar 13
pmlive.com - May 20 at 7:17 PM
ALNY Makes Bullish Cross Above Critical Moving AverageALNY Makes Bullish Cross Above Critical Moving Average
nasdaq.com - May 20 at 2:17 PM
Alnylam Pharmaceuticals Stock Is Believed To Be Possible Value TrapAlnylam Pharmaceuticals Stock Is Believed To Be Possible Value Trap
gurufocus.com - May 17 at 8:12 PM
Heres Why Alnylam Pharmaceuticals, Inc.s (NASDAQ:ALNY) CEO Might See A Pay Rise SoonHere's Why Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) CEO Might See A Pay Rise Soon
nasdaq.com - May 12 at 9:48 AM
Alnylam Announces New Advances in ATTR Amyloidosis ProgramAlnylam Announces New Advances in ATTR Amyloidosis Program
finance.yahoo.com - May 11 at 7:26 AM
Regeneron Pharmaceuticals Inc (REGN) Q1 2021 Earnings Call TranscriptRegeneron Pharmaceuticals Inc (REGN) Q1 2021 Earnings Call Transcript
msn.com - May 6 at 4:30 PM
Evercore ISI Stick to Their Buy Rating for Alnylam PharmaceuticalsEvercore ISI Stick to Their Buy Rating for Alnylam Pharmaceuticals
investing.com - May 3 at 10:06 AM
DateCompanyBrokerageAction
3/2/2021CatalentArgusBoost Price Target
2/3/2021CatalentMorgan StanleyBoost Price Target
2/3/2021CatalentUBS GroupBoost Price Target
2/3/2021CatalentRoyal Bank of CanadaBoost Price Target
1/8/2021CatalentJPMorgan Chase & Co.Boost Price Target
11/5/2020CatalentDeutsche Bank AktiengesellschaftBoost Price Target
11/4/2020CatalentRobert W. BairdBoost Price Target
11/4/2020CatalentJefferies Financial GroupBoost Price Target
6/17/2021CureVacBank of AmericaDowngrade
5/3/2021CureVacGuggenheimInitiated Coverage
4/26/2021CureVacCredit Suisse GroupInitiated Coverage
11/17/2020CureVacBerenberg BankReiterated Rating
6/15/2020UCBBarclaysReiterated Rating
10/16/2019UCBCitigroupUpgrade
5/27/2021Horizon Therapeutics PublicMaxim GroupReiterated Rating
3/18/2021Horizon Therapeutics PublicCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellReiterated Rating
3/17/2021Horizon Therapeutics PublicStifel NicolausBoost Price Target
3/11/2021Horizon Therapeutics PublicWolfe ResearchInitiated Coverage
11/3/2020Horizon Therapeutics PublicBMO Capital MarketsBoost Price Target
7/22/2020Horizon Therapeutics PublicPiper SandlerBoost Price Target
4/20/2021Alnylam PharmaceuticalsNeedham & Company LLCReiterated Rating
2/12/2021Alnylam PharmaceuticalsHC WainwrightBoost Price Target
1/13/2021Alnylam PharmaceuticalsCowenBoost Price Target
11/24/2020Alnylam PharmaceuticalsSVB LeerinkBoost Price Target
10/12/2020Alnylam PharmaceuticalsChardan CapitalReiterated Rating
9/30/2020Alnylam PharmaceuticalsOppenheimerReiterated Rating
(Data available from 6/18/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.